| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 7, 2003
Accepted on August 21, 2003
1 Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine (Y.H., N.K., K.M., K.N.), Kyoto 606-8507, Japan; Translational Research Center (T.A., H.H., K.K.), Kyoto University Hospital, Kyoto 606-8507, Japan; and Department of Biochemistry, National Cardiovascular Center Research Institute (H.H., K.K.), Osaka 565-8565, Japan
* To whom correspondence should be addressed. E-mail: akataka{at}kuhp.kyoto-u.ac.jp.
Ghrelin not only strongly stimulates growth hormone (GH) secretion, but is also involved in energy homeostasis by stimulating food intake and promoting adiposity through a GH-independent mechanism. These effects of ghrelin may play an important role in the pathophysiology of inflammatory wasting syndrome, in which both the somatotropic axis and energy balance are altered. In this study, we investigated plasma ghrelin concentrations after lipopolysaccharide (LPS) administration to rats, a model of the wasting syndrome and critical illness. In addition, the therapeutic potential of the anti-wasting effects of ghrelin was explored using LPS-injected rats. A single LPS injection suppressed plasma ghrelin levels 6 h and 12 h later. Maximal reduction was observed 12 h after LPS injection, in a dose-dependent manner. In contrast, plasma ghrelin levels were elevated after repeated LPS injections on day 2 and day 5. Peripheral administration of ghrelin twice daily (10 nmol/rat) for 5 days increased body weight gain in repeated LPS injected rats. Furthermore, both adipose tissue weight and plasma leptin concentrations were increased following ghrelin administration in these rats. In conclusion, plasma ghrelin levels are altered in LPS-injected rats, and ghrelin treatment may provide a new therapeutic approach to the wasting syndrome and critical illness.
This article has been cited by other articles:
 |
|
 |
|
  L. D Madison, J. M Scarlett, P. Levasseur, X. Zhu, K. Newcomb, A. Batra, D. Bowe, and D. L Marks Prostacyclin signaling regulates circulating ghrelin during acute inflammation J. Endocrinol., February 1, 2008; 196(2): 263 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. DeBoer, X. Zhu, P. R. Levasseur, A. Inui, Z. Hu, G. Han, W. E. Mitch, J. E. Taylor, H. A. Halem, J. Z. Dong, et al. Ghrelin Treatment of Chronic Kidney Disease: Improvements in Lean Body Mass and Cytokine Profile Endocrinology, February 1, 2008; 149(2): 827 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E131 - E141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vila, C. Maier, M. Riedl, P. Nowotny, B. Ludvik, A. Luger, and M. Clodi Bacterial Endotoxin Induces Biphasic Changes in Plasma Ghrelin in Healthy Humans J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3930 - 3934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, N. R. Basa, A. Shaikh, A. Luckey, D. Heber, D. H. St-Pierre, and Y. Tache LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications. Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G611 - G620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Granado, T. Priego, A. I. Martin, M{a} A. Villanua, and A. Lopez-Calderon Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1007 - E1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chiesa, J. F. Osborn, L. Pacifico, G. Tellan, P. M. Strappini, R. Fazio, and G. Delogu Circulating Ghrelin in Patients Undergoing Elective Cholecystectomy Clin. Chem., July 1, 2005; 51(7): 1258 - 1261. [Full Text] [PDF]
|
|
|
|
|
|
M. Granado, T. Priego, A. I. Martin, M. A. Villanua, and A. Lopez-Calderon Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E486 - E492. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
